Morning Overview on MSN
Intismeran autogene plus Keytruda dropped melanoma recurrence by close to 50% over five years in a Moderna-Merck-NYU trial unveiled at ASCO
Patients with high-risk melanoma who received a personalized mRNA cancer vaccine alongside Keytruda saw their risk of disease ...
With $500 million in funding and a reported $2.5 billion valuation, Flourish wants to reinvent AI by putting real neurons ...
Objectives To determine the prevalence and clinical characteristics associated with polyneuropathy in kidney transplant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results